Apixaban

Overview

Apixaban is an oral anticoagulant medication that works by inhibiting factor Xa, an important component in the blood coagulation pathway. It is commonly used to prevent and treat blood clots and reduce the risk of stroke in patients with atrial fibrillation.

API suppliers (11)

Suppliers of Apixaban backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Zhejiang Hisun Pharmaceutical Co., Ltd.China3 active DMF
• DELMAR CHEMICALS INCCanada1 active DMF
• Cipla USA, Inc.USA1 active DMF
• DELMAR CHEMICALS INCCanada1 active DMF
• DELMAR CHEMICALS INCCanada1 active DMF
• Cipla USA, Inc.USA1 active DMF
• Zydus Lifesciences LimitedIndia1 active DMF
• Zakłady Farmaceutyczne Polpharma S.A.Poland1 active DMF
• APOTEX PHARMACHEM INC
• WATSON PHARMA PRIVATE LTD
• SINTENOVO SA DE CV

Patent & exclusivity (US)

Per the FDA Orange Book (8 approved US products), the latest listed US patent on Apixaban expires 21 May 2041 and exclusivity 16 Oct 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas